The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
TLR8 (Toll-like receptor 8, also known as CD288) is a member of the Toll-like receptor family of pattern recognition receptors fundamental to innate immunity (martinezespinoza2022therelevanceof pages 1-2). The human TLR8 gene (UniProt accession Q9NR97) encodes a type I transmembrane glycoprotein that functions as an endosomal sensor of pathogen-derived nucleic acids, particularly single-stranded RNA (ssRNA) (sakaniwa2020targetingtheinnate pages 4-6, martinezespinoza2022therelevanceof pages 1-2). TLR8 is evolutionarily conserved across vertebrates and belongs to the TLR7 subfamily, which specializes in detecting nucleic acid-based pathogen-associated molecular patterns (PAMPs) within intracellular compartments (sakaniwa2020targetingtheinnate pages 4-6).
TLR8 serves as an endosomal pattern recognition receptor whose primary function is to detect viral and bacterial RNA degradation products and initiate downstream innate immune responses (martinezespinoza2022therelevanceof pages 1-2, sakaniwa2020targetingtheinnate pages 4-6). Unlike enzymatic proteins, TLR8 does not catalyze chemical reactions; rather, it functions as a signaling receptor that converts extracellular recognition of nucleic acid ligands into intracellular inflammatory and antimicrobial signaling cascades (sakaniwa2020targetingtheinnate pages 4-6).
Recent structural and biochemical studies have revealed that TLR8 employs a sophisticated dual-site ligand recognition mechanism (ekimoto2024synergisticactivationof pages 1-2, behzadi2021tolllikereceptorsgeneral pages 13-14). The receptor recognizes:
Small-molecule ligands at a conserved first binding site located at the dimer interface, with uridine being the primary natural nucleoside ligand (behzadi2021tolllikereceptorsgeneral pages 13-14, sakaniwa2020targetingtheinnate pages 4-6, wang2022moleculardynamicssimulations pages 1-2). Key residues involved in this interaction include Phe405 and Asp543, along with contributions from Tyr348, Val520, and Thr574 (sakaniwa2020targetingtheinnate pages 6-8).
Oligoribonucleotide ligands at a distinct second binding site on the concave leucine-rich repeat (LRR) surface, primarily involving LRR9-13 and portions of the characteristic Z-loop insertion (ekimoto2024synergisticactivationof pages 1-2, behzadi2021tolllikereceptorsgeneral pages 13-14). This site preferentially binds guanosine-rich ssRNA sequences.
TLR8 responds to AU-rich and GU-rich ssRNA sequences, as well as RNA secondary structures (behzadi2021tolllikereceptorsgeneral pages 13-14, martinezespinoza2022therelevanceof pages 1-2). Importantly, TLR8 can distinguish self from non-self RNA through differential recognition of nucleoside modifications: unmodified foreign RNA is generally more stimulatory than host RNA containing immunosuppressive nucleoside modifications (martinezespinoza2022therelevanceof pages 1-2). This mechanism allows TLR8 to preferentially respond to microbial RNA while maintaining tolerance to modified host RNA under normal conditions.
Molecular dynamics studies have demonstrated that ligand binding at these two sites works synergistically: the first-site ligand directly stabilizes the active dimer interface, while second-site oligonucleotide binding allosterically reduces electrostatic repulsion between receptor protomers, lowering the energetic barrier for productive dimerization (ekimoto2024synergisticactivationof pages 1-2).
While TLR8 and TLR7 share high sequence homology and both detect RNA, they exhibit distinct ligand preferences and biological outputs (wang2022moleculardynamicssimulations pages 1-2, sakaniwa2020targetingtheinnate pages 4-6). TLR7 preferentially recognizes guanosine and guanosine derivatives, whereas TLR8 functions as a uridine receptor (wang2022moleculardynamicssimulations pages 1-2, sakaniwa2020targetingtheinnate pages 4-6). These differences in nucleoside specificity translate to distinct cellular distributions and signaling outcomes, with TLR7 predominantly expressed in plasmacytoid dendritic cells (pDCs) and B cells, while TLR8 is mainly expressed in myeloid cells (wang2022moleculardynamicssimulations pages 1-2, hamerman2024thepathahead pages 3-4).
| Feature | TLR7 | TLR8 |
|---|---|---|
| Receptor class and location | Endosomal nucleic-acid-sensing Toll-like receptor; detects RNA within endolysosomal compartments. | Endosomal nucleic-acid-sensing Toll-like receptor; transported from the ER to endosomes by UNC93B1 and functions at the endosomal membrane. (ao2021thesignalpeptide pages 8-11, sakaniwa2020targetingtheinnate pages 4-6, hofsten2024humanandmurine pages 10-11) |
| Preferred nucleoside | Preferentially recognizes guanosine and guanosine derivatives. (wang2022moleculardynamicssimulations pages 1-2, sakaniwa2020targetingtheinnate pages 4-6) | Preferentially recognizes uridine. (behzadi2021tolllikereceptorsgeneral pages 13-14, wang2022moleculardynamicssimulations pages 1-2, sakaniwa2020targetingtheinnate pages 4-6) |
| RNA specificity | Recognizes ssRNA; reported preference includes UU-containing or uridine-rich sequences acting cooperatively with guanosine. (behzadi2021tolllikereceptorsgeneral pages 13-14, sakaniwa2020targetingtheinnate pages 4-6) | Recognizes RNA-degradation products through two sites: uridine binds the conserved first site, while short oligoribonucleotides—often GU- or guanosine-rich—bind a second site; AU- and GU-rich ssRNA and RNA secondary structure can stimulate the receptor. (behzadi2021tolllikereceptorsgeneral pages 13-14, ekimoto2024synergisticactivationof pages 1-2, martinezespinoza2022therelevanceof pages 1-2) |
| Representative synthetic agonists | Imiquimod is TLR7-selective; resiquimod/R848, CL075, and CL097 can activate both TLR7 and TLR8. (martinezespinoza2022therelevanceof pages 2-4, sakaniwa2020targetingtheinnate pages 8-10) | TL8-506, selgantolimod/GS-9688, motolimod/VTX-2337, and CL075 are TLR8-active agonists; R848, CL075, and CL097 can also activate TLR7. (sakaniwa2020targetingtheinnate pages 8-10, talukdar2021structuralevolutionand pages 14-16, kaushik2021structuralevolutionof pages 2-3, martinezespinoza2022therelevanceof pages 2-4) |
| Predominant human cellular expression | Mainly plasmacytoid dendritic cells and B cells; also detectable in some monocyte contexts. (wang2022moleculardynamicssimulations pages 1-2, hamerman2024thepathahead pages 3-4, martinezespinoza2022therelevanceof pages 4-6) | Predominantly neutrophils, monocytes, macrophages, myeloid dendritic cells, and some regulatory T cells; generally absent from plasmacytoid dendritic cells and B cells according to recent expert review. (martinezespinoza2022therelevanceof pages 1-2, hamerman2024thepathahead pages 3-4) |
| Core signaling architecture | MyD88-dependent signaling with IRF5/IRF7, NF-κB, and MAPK branches; pDC responses strongly favor type I interferon production. (wang2022moleculardynamicssimulations pages 1-2, behzadi2021tolllikereceptorsgeneral pages 13-14) | Principally MyD88-dependent: TIRAP/MyD88 → IRAK4/IRAK1 → TRAF6 → TAK1–TAB → IKK/NF-κB and MAPKs/AP-1; IRF3/5/7-associated branches can support type I interferon responses. (martinezespinoza2022therelevanceof pages 4-6, lannoy2023tiraptramand pages 3-5, salauddin2025roleoftlrs pages 5-7) |
| Dominant transcriptional outcome | In pDCs, strong IRF7-centered type I interferon response, particularly IFN-α; in CD14+ monocytes, TLR7 signaling is comparatively weak. (wang2022moleculardynamicssimulations pages 1-2, hamerman2024thepathahead pages 3-4, martinezespinoza2022therelevanceof pages 4-6) | Strong NF-κB-driven inflammatory transcription in myeloid cells; in CD14+ monocytes, TLR8 generally dominates the response to dual agonists such as R848. (hamerman2024thepathahead pages 3-4, wang2022moleculardynamicssimulations pages 1-2) |
| Characteristic cytokines | Especially IFN-α1 and IFN-α2 in monocytes and pDCs, together with context-dependent inflammatory cytokines. (martinezespinoza2022therelevanceof pages 4-6) | Potently induces TNF-α, IL-1α/β, IL-6, IL-8, IL-12β, IL-27, MIP-1α and, in some monocyte or myeloid-DC settings, IFN-β. (martinezespinoza2022therelevanceof pages 4-6) |
| Principal immune role | Antiviral sensing centered on pDC interferon production and B-cell activation; excessive activity promotes autoreactive B-cell expansion and nucleic-acid-driven autoimmunity. (hamerman2024thepathahead pages 3-4) | RNA sensing and vigorous inflammatory activation of myeloid cells; promotes antigen presentation, Th1 and T-follicular-helper differentiation, CD8 T-cell priming, and reversal of regulatory-T-cell suppression in some settings. (martinezespinoza2022therelevanceof pages 1-2, martinezespinoza2022therelevanceof pages 6-8) |
| Disease associations | Strongly implicated in SLE through excess type I interferon production, autoreactive B-cell activation, gene dosage, and gain-of-function signaling. (hamerman2024thepathahead pages 3-4, hofsten2024humanandmurine pages 10-11) | Human gain-of-function variants are associated with neutropenia, cytopenias, hypogammaglobulinemia, hepatosplenomegaly, hemophagocytosis, and inflammatory or autoimmune manifestations; links to systemic juvenile idiopathic arthritis and adult-onset Still’s disease have also been reported. (hamerman2024thepathahead pages 3-4) |
| Reciprocal regulation and species caveat | Can be restrained by TLR8 in some dendritic-cell and mouse-model contexts; TLR7-dependent disease is exacerbated when murine Tlr8 is deleted. (hofsten2024humanandmurine pages 10-11, hofsten2024humanandmurine pages 8-10) | Can restrain TLR7 expression or responsiveness in some models, but human TLR8 is also an autonomous pro-inflammatory receptor. Mouse TLR8 biology differs substantially from human TLR8, limiting direct extrapolation from conventional mouse models. (hamerman2024thepathahead pages 3-4, hofsten2024humanandmurine pages 10-11, hamerman2024thepathahead pages 1-3) |
Table: This table contrasts TLR7 and TLR8 ligand recognition, cellular distribution, signaling outputs, immune functions, and disease associations. It highlights why human TLR8 is best understood as a uridine-sensitive, myeloid-cell inflammatory RNA sensor rather than simply a duplicate of TLR7.
TLR8 is a type I transmembrane protein comprising an N-terminal signal peptide, a large extracellular ectodomain containing approximately 26 leucine-rich repeats (LRRs), a single transmembrane helix, and a cytoplasmic Toll/interleukin-1 receptor (TIR) domain (martinezespinoza2022therelevanceof pages 1-2, sakaniwa2020targetingtheinnate pages 4-6). A distinctive structural feature is the Z-loop insertion between LRR14 and LRR15, which contributes to ligand recognition and receptor activation (sakaniwa2020targetingtheinnate pages 4-6).
Unlike many other TLRs, TLR8 exists as a preformed inactive homodimer prior to ligand binding (asami2021structuralandfunctional pages 5-7, asami2021structuralandfunctional pages 3-5). Structural studies reveal that in the unliganded state, the two protomers adopt an open, face-to-face arrangement with their C-terminal regions separated by approximately 50 Å (sakaniwa2020targetingtheinnate pages 6-8). Agonist binding induces a substantial conformational reorganization that brings the C-terminal regions to approximately 30 Å apart, creating the geometry necessary for productive association of the cytoplasmic TIR domains (ekimoto2024synergisticactivationof pages 1-2, sakaniwa2020targetingtheinnate pages 6-8). This C-terminal approximation enables recruitment of downstream adaptor proteins and initiation of signaling (sakaniwa2020targetingtheinnate pages 1-4).
Antagonists, in contrast, occupy hydrophobic pockets at the protomer interface and stabilize the inactive dimer conformation, preventing the activating conformational transition and blocking agonist access (asami2021structuralandfunctional pages 5-7). This mechanism has been exploited in structure-based drug design efforts to develop TLR8-selective antagonists for therapeutic applications (sakaniwa2020targetingtheinnate pages 8-10, betschart2022structurebasedoptimizationof pages 7-7).
TLR8 is predominantly localized to endosomal and endolysosomal compartments, where it performs its ligand-recognition function on the luminal side of the endosomal membrane (ao2021thesignalpeptide pages 8-11, martinezespinoza2022therelevanceof pages 2-4, sakaniwa2020targetingtheinnate pages 4-6). This subcellular distribution is critical for TLR8 function, as it enables the receptor to inspect internalized nucleic acids derived from phagocytosed pathogens, endocytosed immune complexes, or viral infection while limiting indiscriminate recognition of extracellular or cytosolic self-RNA (sakaniwa2020targetingtheinnate pages 4-6).
The trafficking of TLR8 to endosomes is an actively regulated process. Following synthesis in the endoplasmic reticulum, TLR8 requires both its signal peptide and the chaperone protein UNC93B1 for proper transport to endosomal compartments (ao2021thesignalpeptide pages 8-11, ao2021thesignalpeptide pages 5-8, hofsten2024humanandmurine pages 10-11). Studies using knockout approaches have demonstrated that loss of UNC93B1 or deletion of the TLR8 signal peptide disrupts endosomal localization, confirming these elements as essential for correct subcellular targeting (ao2021thesignalpeptide pages 8-11).
Co-localization experiments have shown that TLR8 associates with early endosome markers (Rab5) and the endoplasmic reticulum during trafficking, but not with Golgi (GM130) or lysosomal (LAMP1) markers under basal conditions (ao2021thesignalpeptide pages 5-8). This endosomal localization distinguishes TLR8 from cell-surface TLRs and is shared with other nucleic acid-sensing TLRs including TLR7 and TLR9 (rodrigues2024tlr10anintriguing pages 2-3, hofsten2024humanandmurine pages 10-11).
TLR8 exhibits a distinct cellular expression pattern that differs markedly from its close relative TLR7. TLR8 is predominantly expressed in CD14-positive monocytes, macrophages, neutrophils, myeloid dendritic cells, and certain T cell subsets including regulatory T cells (martinezespinoza2022therelevanceof pages 1-2, hamerman2024thepathahead pages 3-4, wang2022moleculardynamicssimulations pages 1-2). Notably, TLR8 is generally absent from plasmacytoid dendritic cells and B cells, which are the primary sites of TLR7 expression (hamerman2024thepathahead pages 3-4). This differential cellular distribution underlies the distinct immunological roles of these two receptors, with TLR8 primarily mediating myeloid inflammatory responses while TLR7 drives interferon production in pDCs (hamerman2024thepathahead pages 3-4).
TLR8 signals predominantly through the MyD88-dependent pathway (sakaniwa2020targetingtheinnate pages 4-6, mantovani2023tlrsinnateimmune pages 3-4). Upon ligand-induced conformational change and TIR domain approximation, TLR8 recruits the adaptor proteins TIRAP (also known as MAL) and MyD88 to initiate downstream signaling (mantovani2023tlrsinnateimmune pages 3-4, lannoy2023tiraptramand pages 3-5). Recent evidence indicates that TIRAP plays a particularly important role in human TLR8 signaling, with disruption of the TIRAP-MyD88 interaction selectively blocking TLR8-induced interferon regulatory factor 5 (IRF5)-dependent responses (nilsen2025anoveltirapmyd88 pages 31-34).
The canonical TLR8 signaling pathway proceeds as follows: TLR8 → TIRAP/MyD88 → IRAK4 → IRAK1 → TRAF6 → TAK1-TAB1/TAB2/TAB3 complex → IKK complex and MAP kinases (martinezespinoza2022therelevanceof pages 4-6, salauddin2025roleoftlrs pages 2-4, salauddin2025roleoftlrs pages 5-7). Activation of the IKK complex leads to phosphorylation and degradation of IκB, releasing NF-κB for nuclear translocation and transcriptional activation of inflammatory genes (mantovani2023tlrsinnateimmune pages 3-4, salauddin2025roleoftlrs pages 5-7). Concurrently, MAP kinase activation (including p38, JNK, and ERK) supports AP-1 transcription factor activity (martinezespinoza2022therelevanceof pages 4-6).
In addition to the NF-κB/AP-1 inflammatory branch, TLR8 can activate interferon regulatory factors, particularly IRF3, IRF5, and IRF7, in a context-dependent manner (martinezespinoza2022therelevanceof pages 4-6, nilsen2025anoveltirapmyd88 pages 31-34). This IRF activation enables TLR8 to induce type I interferon responses, particularly IFN-β production (martinezespinoza2022therelevanceof pages 4-6). However, unlike TLR7 in plasmacytoid dendritic cells, which strongly drives IFN-α production, human TLR8 is more strongly associated with inflammatory cytokine production than with robust type I interferon responses in most cell types (martinezespinoza2022therelevanceof pages 4-6).
TLR8 activation leads to production of a characteristic profile of inflammatory mediators, including TNF-α, IL-1α/β, IL-6, IL-8/CXCL8, IL-12, IL-27, and MIP-1α (martinezespinoza2022therelevanceof pages 4-6). In myeloid dendritic cells and monocytes, TLR8 produces a particularly strong inflammatory response, primarily through the TRAF6-NF-κB pathway, which is more robust than the inflammatory response elicited by TLR7 in the same cell types (martinezespinoza2022therelevanceof pages 4-6). In CD14+ monocytes, TLR8 signaling dominates when cells are stimulated with dual TLR7/8 agonists such as resiquimod (R848), reflecting the stronger transcriptional response mediated by TLR8 in myeloid cells (hamerman2024thepathahead pages 3-4).
TLR8 plays a critical role in innate antibacterial and antiviral immunity by detecting microbial RNA within endosomal compartments (martinezespinoza2022therelevanceof pages 1-2). The receptor recognizes RNA from various pathogens including viruses (HIV-1, influenza A, SARS-CoV-2, hepatitis B and C, Zika virus, respiratory syncytial virus, Coxsackie B virus) and bacteria (martinezespinoza2022therelevanceof pages 8-9, martinezespinoza2022therelevanceof pages 4-6, martinezespinoza2022therelevanceof pages 2-4). Recognition of bacterial RNA is particularly important for detecting viable bacteria, as live organisms release mRNA that can activate TLR8 (nilsen2025anoveltirapmyd88 pages 31-34).
The antiviral effects of TLR8 activation are complex and context-dependent. In many viral infections, TLR8 contributes to protective inflammatory responses, cytokine production, and viral clearance (martinezespinoza2022therelevanceof pages 4-6). However, in certain contexts such as HIV-1 infection, TLR8 activation can promote viral replication by inducing cytokines that support HIV reactivation from latency and create a pro-viral cellular environment (martinezespinoza2022therelevanceof pages 2-4). This dual nature has led to investigation of TLR8 agonists both as antiviral therapeutics and as HIV latency-reversing agents (martinezespinoza2022therelevanceof pages 8-9, martinezespinoza2022therelevanceof pages 4-6).
Beyond direct antimicrobial effects, TLR8 plays important roles in connecting innate and adaptive immune responses (martinezespinoza2022therelevanceof pages 1-2). TLR8 activation promotes dendritic cell maturation, upregulates co-stimulatory molecules and MHC class II expression, and enhances antigen presentation capacity (martinezespinoza2022therelevanceof pages 1-2). These effects support the development of productive T cell responses, including Th1 differentiation and the generation of antigen-specific CD8+ T cells with enhanced cytotoxic function (martinezespinoza2022therelevanceof pages 1-2, martinezespinoza2022therelevanceof pages 6-8).
TLR8 also influences T cell subset differentiation. In the context of HIV infection, TLR8 signaling in CD4+ T cells promotes differentiation of T follicular helper cells toward Tfh1 and Tfh17 subsets (martinezespinoza2022therelevanceof pages 6-8). Additionally, TLR8 activation can reverse the suppressive activity of regulatory T cells through MyD88-IRAK4 pathway activation (martinezespinoza2022therelevanceof pages 1-2). These immunomodulatory functions position TLR8 agonists as potential vaccine adjuvants capable of enhancing both humoral and cellular immunity (martinezespinoza2022therelevanceof pages 6-8, martinezespinoza2022therelevanceof pages 9-9).
TLR8 activation also enhances natural killer (NK) cell function, particularly antibody-dependent cellular cytotoxicity (ADCC) (hinkelmann2025murinetolllikereceptor pages 48-53, sakaniwa2020targetingtheinnate pages 8-10). This property has been exploited in developing TLR8 agonists such as motolimod (VTX-2337) for cancer immunotherapy applications (sakaniwa2020targetingtheinnate pages 8-10).
An important aspect of TLR8 biology is its regulatory relationship with TLR7. Studies in mice have revealed that TLR8 can negatively regulate TLR7 expression and responses, particularly in dendritic cells (hofsten2024humanandmurine pages 10-11, martinezespinoza2022therelevanceof pages 1-2). TLR8-deficient mice show increased TLR7 expression in dendritic cells, enhanced responses to TLR7 agonists, elevated NF-κB activation, and increased production of autoantibodies (hofsten2024humanandmurine pages 10-11). This regulatory function appears to be cell-type-specific, as macrophage cytokine production was not affected by TLR8 deficiency in the same studies (hofsten2024humanandmurine pages 10-11).
The mechanism of TLR8-mediated TLR7 regulation is not fully understood but may involve competition for the UNC93B1 chaperone, which traffics both receptors to endosomes (hofsten2024humanandmurine pages 10-11). However, recent evidence suggests more direct regulatory mechanisms may also be involved (hofsten2024humanandmurine pages 10-11). This cross-regulation has important implications for autoimmune disease, as loss of both TLR8 and TLR9 produces more severe lupus-like disease than loss of either receptor alone, suggesting that TLR8 normally helps restrain TLR7-driven autoimmunity (hofsten2024humanandmurine pages 10-11, hofsten2024humanandmurine pages 8-10).
Human genetic studies have revealed important connections between TLR8 dysregulation and inflammatory disease. Gain-of-function TLR8 variants have been associated with diverse clinical manifestations including severe neutropenia, cytopenias, hypogammaglobulinemia, hepatosplenomegaly, elevated pro-inflammatory cytokines, hemophagocytosis, autoimmune thrombocytopenia, and type 1 diabetes (hamerman2024thepathahead pages 3-4). Some patients with TLR8 gain-of-function mutations develop systemic juvenile idiopathic arthritis or adult-onset Still's disease, illustrating TLR8's contribution to autoinflammatory conditions (hamerman2024thepathahead pages 3-4).
The disease spectrum associated with TLR8 dysregulation differs from that of TLR7, which is more strongly linked to systemic lupus erythematosus (SLE) and interferon-driven autoimmunity (hamerman2024thepathahead pages 3-4). TLR8-associated diseases tend to manifest with inflammatory rather than interferon-predominant phenotypes, consistent with TLR8's expression in myeloid cells and its strong NF-κB-driven inflammatory output (hamerman2024thepathahead pages 3-4, hamerman2024thepathahead pages 4-6).
The role of TLR8 in SLE is complex and likely protective rather than pathogenic. While TLR7 excess drives lupus-like disease through B cell and pDC activation, TLR8 appears to restrain this pathology: TLR8 deficiency in lupus-prone mice exacerbates disease in a TLR7-dependent manner, and simultaneous deletion of TLR7 eliminates the disease phenotype caused by TLR8 loss (hofsten2024humanandmurine pages 10-11, hofsten2024humanandmurine pages 8-10). This suggests that therapeutic targeting of TLR8 in autoimmune disease requires careful consideration of the balance between TLR7 and TLR8 signaling (nilsen2025anoveltirapmyd88 pages 31-34, kalliolias2024targetingtlrsignaling pages 1-2).
TLR8 has been implicated in host responses to numerous viral infections with variable outcomes. Reduced TLR8 expression has been associated with impaired cytokine and interferon responses in respiratory syncytial virus, Zika virus, and chronic hepatitis B infections, suggesting that adequate TLR8 activity supports antiviral defense (martinezespinoza2022therelevanceof pages 4-6). Genetic variants in TLR8 can alter susceptibility to or outcomes from HCV and HIV infections (martinezespinoza2022therelevanceof pages 4-6).
During influenza A virus infection, TLR8 contributes to inflammatory signaling and neutrophil activation (martinezespinoza2022therelevanceof pages 2-4). In Coxsackie B virus infection, immune responses are mediated primarily through TLR8 rather than TLR7 (martinezespinoza2022therelevanceof pages 2-4). However, in West Nile virus infection in mice, TLR8 deficiency paradoxically improved antiviral responses through increased TLR7 expression, demonstrating that the net effect of TLR8 signaling can vary depending on the specific pathogen and cellular context (martinezespinoza2022therelevanceof pages 2-4).
TLR8 agonists are being actively developed for multiple therapeutic applications, capitalizing on the receptor's ability to activate myeloid cells and bridge innate and adaptive immunity (sakaniwa2020targetingtheinnate pages 8-10, talukdar2021structuralevolutionand pages 14-16).
Cancer Immunotherapy: TLR8 agonists are being evaluated in oncology as immune adjuvants that can activate tumor-infiltrating immune cells, promote cytokine production, and enhance antitumor immunity (kaushik2021structuralevolutionof pages 2-3, hu2024harnessinginnateimmune pages 30-31). Motolimod (VTX-2337), a selective TLR8 agonist, has been investigated for its ability to enhance NK cell-mediated ADCC in cancer therapy (sakaniwa2020targetingtheinnate pages 8-10). Other agents include intratumoral formulations such as NKTR-262 (a PEGylated TLR7/8 agonist) and TransCon TLR7/8 Agonist (a sustained-release resiquimod formulation), both designed to provide localized immune activation while minimizing systemic toxicity (hu2024harnessinginnateimmune pages 30-31).
Vaccine Adjuvants: The immunostimulatory properties of TLR8 agonists make them attractive vaccine adjuvants (martinezespinoza2022therelevanceof pages 4-6, shao2026tlragonistsas pages 7-8). Preclinical studies have demonstrated that TLR7/8 agonist-adjuvanted vaccines can elicit Th1-skewed antibody responses, enhanced CD8+ T cell priming, and sterilizing immunity in animal models of SARS-CoV-2 and influenza (martinezespinoza2022therelevanceof pages 6-8, martinezespinoza2022therelevanceof pages 9-9, martinezespinoza2022therelevanceof pages 4-6). TLR8 agonists can be conjugated to antigens or formulated with carrier systems to optimize delivery and immune activation (martinezespinoza2022therelevanceof pages 4-6).
Antiviral Therapy: Selgantolimod (GS-9688), an orally bioavailable TLR8 agonist, has advanced to Phase II clinical trials for chronic hepatitis B (NCT03491553, NCT04891770) (talukdar2021structuralevolutionand pages 14-16, martinezespinoza2022therelevanceof pages 4-6, shao2026tlragonistsas pages 7-8). The rationale is that TLR8 activation can enhance innate and adaptive antiviral immunity, increase mucosal-associated invariant T (MAIT) cell frequency, and improve IFN-γ production (shao2026tlragonistsas pages 7-8). TLR8 agonists are also being investigated as HIV latency-reversing agents that could contribute to viral eradication strategies (martinezespinoza2022therelevanceof pages 8-9).
Safety Considerations: A significant limitation of systemic TLR8 agonist administration is the potential for cytokine-mediated toxicity. TLR7/8 agonists can induce cytokine release syndrome with symptoms including fever, headache, myalgia, skin reactions, and exertional dyspnea (shao2026tlragonistsas pages 7-8). These safety concerns have driven development of localized delivery formulations and dose-optimization strategies (hu2024harnessinginnateimmune pages 30-31).
TLR8 antagonists are being developed primarily for autoimmune and autoinflammatory diseases where excessive TLR8 signaling contributes to pathology (sakaniwa2020targetingtheinnate pages 8-10, betschart2022structurebasedoptimizationof pages 7-7). Structure-based drug design has yielded several classes of TLR8 antagonists:
CU-CPT Compounds: The first human TLR8-specific antagonists, including CU-CPT9b, were designed based on structural understanding of how ligands stabilize the inactive TLR8 dimer conformation (sakaniwa2020targetingtheinnate pages 8-10).
Dual TLR7/8 Antagonists: Given the cooperative and sometimes redundant functions of TLR7 and TLR8, dual antagonists have been developed to broadly suppress nucleic acid-sensing TLR signaling (betschart2022structurebasedoptimizationof pages 7-7). M5049 has been described as a selective TLR7/8 inhibitor under development for autoimmune disease treatment (betschart2022structurebasedoptimizationof pages 7-7).
Novel Scaffolds: Recent medicinal chemistry efforts have produced orally bioavailable TLR7/8 antagonists with demonstrated in vivo efficacy in preclinical models, including compounds that selectively target TLR8 at the protein-protein interface (betschart2022structurebasedoptimizationof pages 7-7). Some antagonist programs also target neuropathic pain, based on evidence that TLR8 and endogenous microRNAs contribute to pain signaling in dorsal root ganglia (betschart2022structurebasedoptimizationof pages 7-7).
TLR8 antagonist development remains at earlier stages than agonist development, with most compounds in preclinical or early clinical evaluation rather than advanced clinical trials (sakaniwa2020targetingtheinnate pages 8-10, betschart2022structurebasedoptimizationof pages 7-7).
An important caveat for TLR8 research is that human TLR8 biology differs substantially from that of mice, the most common model organism (hamerman2024thepathahead pages 3-4, hamerman2024thepathahead pages 1-3). Murine TLR8 has reduced functional activity compared to human TLR8, and standard laboratory mouse strains do not fully recapitulate human TLR8-mediated responses (hamerman2024thepathahead pages 1-3). This species difference has important implications: findings from mouse models regarding TLR8 function, ligand specificity, and disease involvement cannot be uncritically extrapolated to human biology (hamerman2024thepathahead pages 1-3).
Therefore, human primary cells, human genetic studies, and humanized mouse models are particularly valuable for understanding human TLR8 function and for therapeutic development (hamerman2024thepathahead pages 3-4, hamerman2024thepathahead pages 1-3). The distinct species-specific properties of TLR8 underscore the importance of validating findings in human-relevant experimental systems.
| Category | Human TLR8 characteristics | Functional significance and evidence |
|---|---|---|
| Identity | TLR8 (CD288); human Toll-like receptor 8; UniProt Q9NR97; type I transmembrane pattern-recognition receptor in the Toll-like receptor family. | Literature identifies human TLR8 as an intracellular RNA sensor, matching the supplied UniProt identity. (martinezespinoza2022therelevanceof pages 1-2) |
| Domain architecture | N-terminal signal peptide; large luminal ectodomain with approximately 26 leucine-rich repeats (LRRs), a cysteine-rich region, and a characteristic Z-loop between LRR14 and LRR15; one transmembrane helix; cytosolic Toll/IL-1 receptor (TIR) domain. | LRRs form the ligand-binding ectodomain, whereas the TIR domain recruits signaling adaptors. Z-loop processing and receptor rearrangement contribute to activation. (martinezespinoza2022therelevanceof pages 1-2, sakaniwa2020targetingtheinnate pages 4-6) |
| Biochemical class | Signaling receptor, not an enzyme or transporter; it has ligands rather than catalytic substrates and does not catalyze a chemical reaction. | Its primary molecular function is to convert detection of endosomal RNA degradation products into MyD88-dependent inflammatory and antimicrobial signaling. (sakaniwa2020targetingtheinnate pages 4-6) |
| Natural ligands | Pathogen-derived and, under pathological conditions, self-derived single-stranded RNA (ssRNA) and RNA degradation products. Viral, bacterial, mitochondrial, microRNA, and ribonucleoprotein-associated RNA can stimulate TLR8. | Endosomal sequestration focuses recognition on RNA delivered through infection, uptake, or phagocytosis, although access of self-RNA can drive inflammation. (martinezespinoza2022therelevanceof pages 1-2, hamerman2024thepathahead pages 3-4, nilsen2025anoveltirapmyd88 pages 31-34) |
| Ligand specificity | Responds to AU-rich and GU-rich ssRNA, RNA secondary structures, free uridine, and short guanosine-rich oligoribonucleotides. Unmodified RNA is generally more stimulatory than host RNA containing immunosuppressive nucleoside modifications. | Current structural understanding indicates that TLR8 detects combinations of RNA catabolites rather than merely binding intact long ssRNA as one undivided ligand. (behzadi2021tolllikereceptorsgeneral pages 13-14, ekimoto2024synergisticactivationof pages 1-2, martinezespinoza2022therelevanceof pages 1-2) |
| First binding site | Conserved site at the dimer interface binds uridine and synthetic small-molecule agonists; important contacts include Phe405 and Asp543, with contributions from Tyr348, Val520, and Thr574. | Ligand binding stabilizes the two protomers in the active dimer configuration. (sakaniwa2020targetingtheinnate pages 6-8, behzadi2021tolllikereceptorsgeneral pages 13-14) |
| Second binding site | Distinct oligonucleotide-binding site on the concave LRR surface, principally involving LRR9–13 and part of the Z-loop. | Occupancy synergizes with first-site ligands by reducing electrostatic repulsion and lowering the energetic barrier to receptor activation. (ekimoto2024synergisticactivationof pages 1-2, behzadi2021tolllikereceptorsgeneral pages 13-14) |
| Synthetic agonists | Resiquimod/R848, CL075, and CL097 activate TLR8 or TLR7/8; more selective TLR8 agonists include motolimod/VTX-2337, selgantolimod/GS-9688, and TL8-506. | These compounds reproduce ligand-induced receptor rearrangement and are used to stimulate inflammatory, antiviral, or antitumor immunity. (sakaniwa2020targetingtheinnate pages 8-10, talukdar2021structuralevolutionand pages 14-16, martinezespinoza2022therelevanceof pages 4-6) |
| Antagonists | TLR8-selective CU-CPT compounds, including CU-CPT9b, and TH1027; dual TLR7/8 antagonist programs include M5049-related compounds. | Antagonists occupy interprotomer pockets and stabilize the inactive dimer, blocking the activating conformational transition; development remains investigational. (asami2021structuralandfunctional pages 5-7, sakaniwa2020targetingtheinnate pages 8-10, betschart2022structurebasedoptimizationof pages 7-7) |
| Activation mechanism | TLR8 exists as a preformed inactive homodimer. Agonist binding reorganizes the dimer and reduces the separation between ectodomain C termini from approximately 50 Å to 30 Å. | C-terminal approximation permits productive association of cytosolic TIR domains and recruitment of downstream adaptors. (ekimoto2024synergisticactivationof pages 1-2, sakaniwa2020targetingtheinnate pages 6-8, asami2021structuralandfunctional pages 5-7) |
| Subcellular localization | Predominantly an endosomal/endolysosomal membrane receptor; ligand recognition occurs on the luminal side, while signaling begins through cytosolic TIR domains. | This topology enables TLR8 to inspect internalized nucleic acids while limiting indiscriminate recognition of extracellular or cytosolic self-RNA. (ao2021thesignalpeptide pages 8-11, martinezespinoza2022therelevanceof pages 2-4, sakaniwa2020targetingtheinnate pages 4-6) |
| Trafficking | Synthesized through the endoplasmic reticulum; its signal peptide and the chaperone UNC93B1 support transport to endosomes. | Loss of UNC93B1 or disruption of the signal peptide impairs endosomal localization, showing that localization is actively regulated. (ao2021thesignalpeptide pages 8-11, ao2021thesignalpeptide pages 5-8, hofsten2024humanandmurine pages 10-11) |
| Cellular expression | Strongly associated with CD14-positive monocytes, macrophages, neutrophils, myeloid dendritic cells, and subsets of T cells, including regulatory T cells; functional activity also occurs in NK-cell contexts. | TLR8 is primarily a myeloid inflammatory sensor. In human monocytes it frequently dominates responses to dual TLR7/8 agonists. (martinezespinoza2022therelevanceof pages 1-2, hamerman2024thepathahead pages 3-4, wang2022moleculardynamicssimulations pages 1-2) |
| Proximal signaling | Ligand-induced TIR-domain juxtaposition recruits MyD88; evidence supports participation of TIRAP/MAL, followed by IRAK4 and IRAK1 in a Myddosome-like complex. | TLR8 uses a MyD88-dependent pathway rather than the TRIF-dominant pathway of TLR3; TIRAP requirements may vary by cell type and signaling branch. (mantovani2023tlrsinnateimmune pages 3-4, lannoy2023tiraptramand pages 3-5, martinezespinoza2022therelevanceof pages 1-2) |
| Core inflammatory pathway | TLR8 → TIRAP/MyD88 → IRAK4/IRAK1 → TRAF6 → TAK1–TAB1/TAB2/3 → IKK and MAPKs. | IKK releases NF-κB from IκB inhibition, while MAPKs support AP-1 activity; together they drive inflammatory gene expression. (martinezespinoza2022therelevanceof pages 4-6, salauddin2025roleoftlrs pages 2-4, salauddin2025roleoftlrs pages 5-7) |
| Interferon branch | Context-dependent activation of IRF3, IRF5, and IRF7, with possible participation of Akt and IKK-family signaling. | This supports IFN-β and antiviral responses, although human TLR8 is more strongly associated with inflammatory cytokines than the TLR7-driven IFN-α response of plasmacytoid dendritic cells. (martinezespinoza2022therelevanceof pages 4-6, nilsen2025anoveltirapmyd88 pages 31-34) |
| Major outputs | TNF-α, IL-1α/β, IL-6, IL-8/CXCL8, IL-12, IL-27, MIP-1α, and context-dependent type I interferons, especially IFN-β. | Output varies with cell type, ligand, dose, and infection; excessive signaling can cause harmful inflammation as well as antimicrobial protection. (martinezespinoza2022therelevanceof pages 4-6) |
| Primary functions | Detects microbial RNA and initiates innate antibacterial and antiviral immunity, including inflammatory transcription, chemokine release, leukocyte activation, and enhanced antigen presentation. | TLR8 connects phagosomal or endosomal microbial degradation to immune activation and helps recognize viable bacteria through bacterial RNA. (martinezespinoza2022therelevanceof pages 1-2, nilsen2025anoveltirapmyd88 pages 31-34) |
| Innate–adaptive linkage | Promotes dendritic-cell maturation, costimulatory and MHC-II expression, Th1 and T-follicular-helper differentiation, antigen-specific CD8-positive T-cell priming, and NK-cell antibody-dependent cellular cytotoxicity; it can reduce regulatory T-cell suppression. | These functions underpin development of TLR8 agonists as vaccine adjuvants and cancer immunotherapies. (martinezespinoza2022therelevanceof pages 1-2, martinezespinoza2022therelevanceof pages 6-8) |
| Infection examples | Studied in HIV-1, influenza A, SARS-CoV-2, hepatitis B and C, Zika virus, respiratory syncytial virus, and Coxsackie B virus infections. | Effects are context-dependent: TLR8 can improve antiviral defense but may also promote immunopathology, neutrophil activation, or HIV latency reversal and replication-supporting cytokines. (martinezespinoza2022therelevanceof pages 8-9, martinezespinoza2022therelevanceof pages 4-6, martinezespinoza2022therelevanceof pages 2-4) |
| Disease relevance | Human TLR8 gain-of-function variants are associated with neutropenia or other cytopenias, low IgG, hepatosplenomegaly, elevated inflammatory cytokines, and hemophagocytosis; links to systemic juvenile idiopathic arthritis and adult-onset Still’s disease are under investigation. | Human genetics supports a causal role for dysregulated TLR8 signaling in inflammatory disease, although its contribution to common autoimmune disorders is less established than TLR7’s. (hamerman2024thepathahead pages 3-4, hamerman2024thepathahead pages 4-6, hamerman2024thepathahead pages 1-3) |
| Therapeutic applications | Agonists are being explored as vaccine adjuvants, antiviral agents, HIV latency-reversing agents, and cancer immunotherapies; antagonists are being developed for autoimmune and autoinflammatory disease. | Selgantolimod underwent phase II evaluation in chronic hepatitis B, while motolimod and localized TLR7/8 formulations have been studied in oncology. Systemic agonism can cause cytokine-mediated toxicity. (talukdar2021structuralevolutionand pages 14-16, martinezespinoza2022therelevanceof pages 4-6, hu2024harnessinginnateimmune pages 30-31) |
| Translational caveat | Human TLR8 findings should not be inferred uncritically from conventional mouse models because ligand sensing and function differ substantially between species. | Human primary cells, human genetics, and appropriate humanized models are particularly important for functional annotation and therapeutic development. (hamerman2024thepathahead pages 3-4, hamerman2024thepathahead pages 1-3) |
Table: This table consolidates the identity, architecture, ligand recognition, localization, signaling, cellular functions, disease relevance, and therapeutic targeting of human TLR8 (UniProt Q9NR97). It emphasizes evidence supporting TLR8 as an endosomal RNA-degradation-product sensor that drives predominantly MyD88-dependent myeloid inflammatory responses.
TLR8 is an endosomal pattern recognition receptor that detects RNA degradation products through a sophisticated dual-site binding mechanism involving uridine and oligoribonucleotide ligands (ekimoto2024synergisticactivationof pages 1-2, behzadi2021tolllikereceptorsgeneral pages 13-14). The receptor exists as a preformed inactive homodimer that undergoes ligand-induced conformational reorganization to initiate MyD88-dependent signaling cascades (sakaniwa2020targetingtheinnate pages 6-8, asami2021structuralandfunctional pages 5-7). TLR8 is predominantly expressed in myeloid immune cells where it drives potent NF-κB-mediated inflammatory cytokine production (hamerman2024thepathahead pages 3-4, wang2022moleculardynamicssimulations pages 1-2).
The receptor plays critical roles in antibacterial and antiviral immunity, bridges innate and adaptive immune responses, and engages in complex cross-regulatory relationships with TLR7 (martinezespinoza2022therelevanceof pages 1-2, hofsten2024humanandmurine pages 10-11). Dysregulated TLR8 signaling contributes to autoinflammatory diseases, while the receptor appears to play a protective role in restraining TLR7-driven autoimmunity (hamerman2024thepathahead pages 3-4, hofsten2024humanandmurine pages 10-11).
TLR8 represents an attractive therapeutic target with both agonists and antagonists in development. Agonists are being evaluated as vaccine adjuvants, cancer immunotherapies, and antiviral agents, with selgantolimod reaching Phase II clinical trials for chronic hepatitis B (talukdar2021structuralevolutionand pages 14-16, martinezespinoza2022therelevanceof pages 4-6). Antagonists are being developed for autoimmune and autoinflammatory conditions, though clinical development remains at earlier stages (betschart2022structurebasedoptimizationof pages 7-7).
Recent advances in structural biology have illuminated the molecular mechanisms of TLR8 activation and inhibition, enabling rational drug design (ekimoto2024synergisticactivationof pages 1-2, sakaniwa2020targetingtheinnate pages 6-8). However, important questions remain regarding the precise mechanisms of TLR8 regulation, its cell-type-specific functions, the determinants of its cross-regulation with TLR7, and the optimal therapeutic strategies for modulating TLR8 activity in human disease (hamerman2024thepathahead pages 3-4, hamerman2024thepathahead pages 4-6). Continued research using human-relevant experimental systems will be essential for fully understanding TLR8 biology and successfully translating this knowledge into clinical applications (hamerman2024thepathahead pages 1-3).
References
(martinezespinoza2022therelevanceof pages 1-2): Iván Martínez-Espinoza and Antonieta Guerrero-Plata. The relevance of tlr8 in viral infections. Pathogens, 11:134, Jan 2022. URL: https://doi.org/10.3390/pathogens11020134, doi:10.3390/pathogens11020134. This article has 69 citations.
(sakaniwa2020targetingtheinnate pages 4-6): Kentaro Sakaniwa and Toshiyuki Shimizu. Targeting the innate immune receptor tlr8 using small-molecule agents. Acta Crystallographica. Section D, Structural Biology, 76:621-629, Jun 2020. URL: https://doi.org/10.1107/s2059798320006518, doi:10.1107/s2059798320006518. This article has 30 citations.
(ekimoto2024synergisticactivationof pages 1-2): Toru Ekimoto, Masami Nomura, Yuri Saito, Minami Suzuki, Tsutomu Yamane, Zhikuan Zhang, Umeharu Ohto, Mitsunori Ikeguchi, and Toshiyuki Shimizu. Synergistic activation of tlr7 and 8 mediated by reduction of electrostatic repulsion. Chemical & pharmaceutical bulletin, 72 11:1005-1013, Nov 2024. URL: https://doi.org/10.1248/cpb.c24-00409, doi:10.1248/cpb.c24-00409. This article has 2 citations and is from a peer-reviewed journal.
(behzadi2021tolllikereceptorsgeneral pages 13-14): Payam Behzadi, Herney Andrés García-Perdomo, and Tomasz M. Karpiński. Toll-like receptors: general molecular and structural biology. Journal of Immunology Research, 2021:1-21, May 2021. URL: https://doi.org/10.1155/2021/9914854, doi:10.1155/2021/9914854. This article has 333 citations and is from a peer-reviewed journal.
(wang2022moleculardynamicssimulations pages 1-2): Xiaoyu Wang, Yu Chen, Steven Zhang, and Jinxia Nancy Deng. Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to tlr7 and tlr8. Apr 2022. URL: https://doi.org/10.1371/journal.pone.0260565, doi:10.1371/journal.pone.0260565. This article has 26 citations and is from a peer-reviewed journal.
(sakaniwa2020targetingtheinnate pages 6-8): Kentaro Sakaniwa and Toshiyuki Shimizu. Targeting the innate immune receptor tlr8 using small-molecule agents. Acta Crystallographica. Section D, Structural Biology, 76:621-629, Jun 2020. URL: https://doi.org/10.1107/s2059798320006518, doi:10.1107/s2059798320006518. This article has 30 citations.
(hamerman2024thepathahead pages 3-4): Jessica A Hamerman and Gregory M Barton. The path ahead for understanding toll-like receptor-driven systemic autoimmunity. Dec 2024. URL: https://doi.org/10.1016/j.coi.2024.102482, doi:10.1016/j.coi.2024.102482. This article has 29 citations and is from a peer-reviewed journal.
(ao2021thesignalpeptide pages 8-11): Da Ao, Xueliang Liu, Sen Jiang, Yulin Xu, Wanglong Zheng, Nanhua Chen, François Meurens, and Jianzhong Zhu. The signal peptide and chaperone unc93b1 both influence tlr8 ectodomain intracellular endosomal localization. Vaccines, 10:14, Dec 2021. URL: https://doi.org/10.3390/vaccines10010014, doi:10.3390/vaccines10010014. This article has 2 citations.
(hofsten2024humanandmurine pages 10-11): Susannah von Hofsten, Kristin Andreassen Fenton, and Hege Lynum Pedersen. Human and murine toll-like receptor-driven disease in systemic lupus erythematosus. May 2024. URL: https://doi.org/10.3390/ijms25105351, doi:10.3390/ijms25105351. This article has 38 citations.
(martinezespinoza2022therelevanceof pages 2-4): Iván Martínez-Espinoza and Antonieta Guerrero-Plata. The relevance of tlr8 in viral infections. Pathogens, 11:134, Jan 2022. URL: https://doi.org/10.3390/pathogens11020134, doi:10.3390/pathogens11020134. This article has 69 citations.
(sakaniwa2020targetingtheinnate pages 8-10): Kentaro Sakaniwa and Toshiyuki Shimizu. Targeting the innate immune receptor tlr8 using small-molecule agents. Acta Crystallographica. Section D, Structural Biology, 76:621-629, Jun 2020. URL: https://doi.org/10.1107/s2059798320006518, doi:10.1107/s2059798320006518. This article has 30 citations.
(talukdar2021structuralevolutionand pages 14-16): Arindam Talukdar, Dipyaman Ganguly, Swarnali Roy, Nirmal Das, and Dipika Sarkar. Structural evolution and translational potential for agonists and antagonists of endosomal toll-like receptors. Jun 2021. URL: https://doi.org/10.1021/acs.jmedchem.1c00300, doi:10.1021/acs.jmedchem.1c00300. This article has 54 citations and is from a highest quality peer-reviewed journal.
(kaushik2021structuralevolutionof pages 2-3): Deepender Kaushik, Arshpreet Kaur, Nikolai Petrovsky, and Deepak B. Salunke. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. RSC medicinal chemistry, 12 7:1065-1120, Jul 2021. URL: https://doi.org/10.1039/d1md00031d, doi:10.1039/d1md00031d. This article has 51 citations and is from a peer-reviewed journal.
(martinezespinoza2022therelevanceof pages 4-6): Iván Martínez-Espinoza and Antonieta Guerrero-Plata. The relevance of tlr8 in viral infections. Pathogens, 11:134, Jan 2022. URL: https://doi.org/10.3390/pathogens11020134, doi:10.3390/pathogens11020134. This article has 69 citations.
(lannoy2023tiraptramand pages 3-5): Valérie Lannoy, Anthony Côté-Biron, Claude Asselin, and Nathalie Rivard. Tirap, tram, and toll-like receptors: the untold story. Mediators of Inflammation, 2023:1-13, Mar 2023. URL: https://doi.org/10.1155/2023/2899271, doi:10.1155/2023/2899271. This article has 61 citations and is from a peer-reviewed journal.
(salauddin2025roleoftlrs pages 5-7): Md. Salauddin, Debaraj Bhattacharyya, Indranil Samanta, Sukumar Saha, Mengzhou Xue, Md. Golzar Hossain, and Chunfu Zheng. Role of tlrs as signaling cascades to combat infectious diseases: a review. Cellular and Molecular Life Sciences: CMLS, Mar 2025. URL: https://doi.org/10.1007/s00018-025-05631-x, doi:10.1007/s00018-025-05631-x. This article has 43 citations.
(martinezespinoza2022therelevanceof pages 6-8): Iván Martínez-Espinoza and Antonieta Guerrero-Plata. The relevance of tlr8 in viral infections. Pathogens, 11:134, Jan 2022. URL: https://doi.org/10.3390/pathogens11020134, doi:10.3390/pathogens11020134. This article has 69 citations.
(hofsten2024humanandmurine pages 8-10): Susannah von Hofsten, Kristin Andreassen Fenton, and Hege Lynum Pedersen. Human and murine toll-like receptor-driven disease in systemic lupus erythematosus. May 2024. URL: https://doi.org/10.3390/ijms25105351, doi:10.3390/ijms25105351. This article has 38 citations.
(hamerman2024thepathahead pages 1-3): Jessica A Hamerman and Gregory M Barton. The path ahead for understanding toll-like receptor-driven systemic autoimmunity. Dec 2024. URL: https://doi.org/10.1016/j.coi.2024.102482, doi:10.1016/j.coi.2024.102482. This article has 29 citations and is from a peer-reviewed journal.
(asami2021structuralandfunctional pages 5-7): Jinta Asami and Toshiyuki Shimizu. Structural and functional understanding of the toll‐like receptors. Protein Science, 30:761-772, Feb 2021. URL: https://doi.org/10.1002/pro.4043, doi:10.1002/pro.4043. This article has 154 citations and is from a peer-reviewed journal.
(asami2021structuralandfunctional pages 3-5): Jinta Asami and Toshiyuki Shimizu. Structural and functional understanding of the toll‐like receptors. Protein Science, 30:761-772, Feb 2021. URL: https://doi.org/10.1002/pro.4043, doi:10.1002/pro.4043. This article has 154 citations and is from a peer-reviewed journal.
(sakaniwa2020targetingtheinnate pages 1-4): Kentaro Sakaniwa and Toshiyuki Shimizu. Targeting the innate immune receptor tlr8 using small-molecule agents. Acta Crystallographica. Section D, Structural Biology, 76:621-629, Jun 2020. URL: https://doi.org/10.1107/s2059798320006518, doi:10.1107/s2059798320006518. This article has 30 citations.
(betschart2022structurebasedoptimizationof pages 7-7): Claudia Betschart, Michael Faller, Florence Zink, René Hemmig, Jutta Blank, Eric Vangrevelinghe, Marjorie Bourrel, Ralf Glatthar, Dirk Behnke, Kerstin Barker, Andreas Heizmann, Daniela Angst, Pierre Nimsgern, Sébastien Jacquier, Tobias Junt, Géraldine Zipfel, Giulia Ruzzante, Pius Loetscher, Sarah Limonta, Stuart Hawtin, Cedric Bernard Andre, Thomas Boulay, Roland Feifel, and Thomas Knoepfel. Structure-based optimization of a fragment-like tlr8 binding screening hit to an in vivo efficacious tlr7/8 antagonist. ACS medicinal chemistry letters, 13 4:658-664, Mar 2022. URL: https://doi.org/10.1021/acsmedchemlett.1c00696, doi:10.1021/acsmedchemlett.1c00696. This article has 12 citations and is from a peer-reviewed journal.
(ao2021thesignalpeptide pages 5-8): Da Ao, Xueliang Liu, Sen Jiang, Yulin Xu, Wanglong Zheng, Nanhua Chen, François Meurens, and Jianzhong Zhu. The signal peptide and chaperone unc93b1 both influence tlr8 ectodomain intracellular endosomal localization. Vaccines, 10:14, Dec 2021. URL: https://doi.org/10.3390/vaccines10010014, doi:10.3390/vaccines10010014. This article has 2 citations.
(rodrigues2024tlr10anintriguing pages 2-3): Carolina Rego Rodrigues, Yadu Balachandran, Gurpreet Kaur Aulakh, and Baljit Singh. Tlr10: an intriguing toll-like receptor with many unanswered questions. Journal of Innate Immunity, 16:96-104, Jan 2024. URL: https://doi.org/10.1159/000535523, doi:10.1159/000535523. This article has 26 citations and is from a peer-reviewed journal.
(mantovani2023tlrsinnateimmune pages 3-4): Stefania Mantovani, Barbara Oliviero, Stefania Varchetta, Alessandra Renieri, and Mario U. Mondelli. Tlrs: innate immune sentries against sars-cov-2 infection. International Journal of Molecular Sciences, 24:8065, Apr 2023. URL: https://doi.org/10.3390/ijms24098065, doi:10.3390/ijms24098065. This article has 84 citations.
(nilsen2025anoveltirapmyd88 pages 31-34): Kaja Elisabeth Nilsen, Jørgen Stenvik, Astrid Skjesol, Ingvild Bergdal Mestvedt, Siril Skaret Bakke, Miriam Soledad Giambelluca, Caroline S. Gravastrand, Kirusika Elamurugan, Liv Ryan, Terje Espevik, and Maria Yurchenko. A novel tirap-myd88 inhibitor blocks tlr7 and tlr8-induced type i ifn responses. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.25.650557, doi:10.1101/2025.04.25.650557. This article has 6 citations.
(salauddin2025roleoftlrs pages 2-4): Md. Salauddin, Debaraj Bhattacharyya, Indranil Samanta, Sukumar Saha, Mengzhou Xue, Md. Golzar Hossain, and Chunfu Zheng. Role of tlrs as signaling cascades to combat infectious diseases: a review. Cellular and Molecular Life Sciences: CMLS, Mar 2025. URL: https://doi.org/10.1007/s00018-025-05631-x, doi:10.1007/s00018-025-05631-x. This article has 43 citations.
(martinezespinoza2022therelevanceof pages 8-9): Iván Martínez-Espinoza and Antonieta Guerrero-Plata. The relevance of tlr8 in viral infections. Pathogens, 11:134, Jan 2022. URL: https://doi.org/10.3390/pathogens11020134, doi:10.3390/pathogens11020134. This article has 69 citations.
(martinezespinoza2022therelevanceof pages 9-9): Iván Martínez-Espinoza and Antonieta Guerrero-Plata. The relevance of tlr8 in viral infections. Pathogens, 11:134, Jan 2022. URL: https://doi.org/10.3390/pathogens11020134, doi:10.3390/pathogens11020134. This article has 69 citations.
(hinkelmann2025murinetolllikereceptor pages 48-53): Lukas Hinkelmann, Mariam Brehm, Victor Kumbol, Hugo McGurran, Christina Krüger, Gunnar Kleinau, Patrick Scheerer, Douglas Golenbock, Lena Alexopoulou, Michael P. Gantier, Stefan Bauer, and Seija Lehnardt. Murine toll-like receptor 8 is a nucleic acid multi-sensor detecting 2’,3’-cyclic monophosphate guanosine as well as combinations of ribo-, deoxy-, cyclic nucleotides, and nucleosides. BioRxiv, Oct 2025. URL: https://doi.org/10.1101/2025.10.14.682277, doi:10.1101/2025.10.14.682277. This article has 1 citations.
(hamerman2024thepathahead pages 4-6): Jessica A Hamerman and Gregory M Barton. The path ahead for understanding toll-like receptor-driven systemic autoimmunity. Dec 2024. URL: https://doi.org/10.1016/j.coi.2024.102482, doi:10.1016/j.coi.2024.102482. This article has 29 citations and is from a peer-reviewed journal.
(kalliolias2024targetingtlrsignaling pages 1-2): George D. Kalliolias, Efthimia K. Basdra, and Athanasios G. Papavassiliou. Targeting tlr signaling cascades in systemic lupus erythematosus and rheumatoid arthritis: an update. Biomedicines, 12:138, Jan 2024. URL: https://doi.org/10.3390/biomedicines12010138, doi:10.3390/biomedicines12010138. This article has 40 citations.
(hu2024harnessinginnateimmune pages 30-31): Ankang Hu, Li Sun, Hao Lin, Yuheng Liao, Hui Yang, and Ying Mao. Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduction and Targeted Therapy, Mar 2024. URL: https://doi.org/10.1038/s41392-024-01765-9, doi:10.1038/s41392-024-01765-9. This article has 312 citations and is from a peer-reviewed journal.
(shao2026tlragonistsas pages 7-8): Fengyan Shao, Xiang-Yu Zhu, Ming Yi, Hongyu Gao, Jiali Wu, Ruikang Fang, Yubiao Xie, Ji-Cheng Han, and Hui-Jun Lu. Tlr agonists as adjuvants for viral vaccines: mechanisms, applications, and future directions. Frontiers in Microbiology, Jan 2026. URL: https://doi.org/10.3389/fmicb.2025.1740572, doi:10.3389/fmicb.2025.1740572. This article has 11 citations and is from a peer-reviewed journal.